Qurient Co (115180.KQ) Stock Price

Qurient Co Price

CLOSED
22,000.00
​
Market closed

Revenue has compounded at 37.2% per year over the past 11 years to 6.98 B KRW. Qurient Co's net margin stands at -430.4%, up from -467.6% several years earlier.

Qurient Co stock price

Access this data via the Eulerpool API

Qurient Co business model & stock analysis

Qurient Co., Ltd. engages in the development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2016-02-29. The firm includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.

Frequently asked questions about Qurient Co

Converted at the current exchange rate, the Qurient Co share trades at 14.33 EUR (22,000.00 KRW).

The revenue cannot currently be calculated for Qurient Co.

The profit cannot currently be calculated for Qurient Co.

The P/E ratio cannot be calculated for Qurient Co at the moment.

The P/S cannot be calculated for Qurient Co currently.

The Eulerpool Quality Score for Qurient Co is 3/10.

The ISIN of Qurient Co is KR7115180002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Qurient Co is 115180.KQ. The ticker symbol is used to trade Qurient Co shares on the stock exchange.

Fair ValueTerminal
18,040.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website qurient.com
Country
South Korea
Currency
KRW
Initial public offering
Feb 29, 2016
ISIN
KR7115180002
Cusip
Y7S695104
Market capitalization
689.70 B KRWMega Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
20.26
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-64.84 %
Gross Margin
13.32 %
EBIT Margin
-426.16 %
Net Margin
-430.41 %
EPS (Earnings Per Share)
-808.20 KRW
Net Debt / EBIT
0.29
Debt/Equity
0.36
Last updated Oct 2, 2026, 7:51 AM

Qurient Co Peer Group

Qurient Co FIGI

115180:KS · BBG0089B97N8115180:KQ · BBG00BCJ8PY9

All fundamentals and in-depth analysis of Qurient Co

Our stock analysis for Qurient Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Qurient Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.